May Neutrophil Gelatinase-Associated Lipocalin (NGAL) Level Predict Mortality in Patients with Hepatocellular Carcinoma (HCC)?
- 46 Downloads
Hepatocellular carcinoma (HCC) ranks fifth among the common cancers worldwide. Hepatocarcinogenesis is a multiple-phases process, which involves changes in cellular genomes including high cell proliferation.In this study, we aimed to evaluate the relationship of NGAL level at the time of diagnosis with mortality in patients diagnosed with HCC.
Material and Methods
A total of 35 patients who developed HCC on the ground of HBV(+) and 30 healthy subjects were included in the study. Barcelona Clinic Liver Cancer (BCLC), Okuda staging system, and Milan criteria were used for staging of the patients with HCC.
The mean age of all patients was 59.54 ± 11.57 years. Seventeen (48.6%) HCC patients died during 1-year follow-up. Survival of the patients who met the Milan criteria was longer (log-rank (Mantel-Cox) test, χ2 = 5.353, p = 0.021). Kaplan-Meier curve was drawn for NGAL cut-off value, mortality was found to be higher in patients with a NGAL level higher than 217.50 (log-rank (Mantel-Cox) test, χ2 = 15.540, p < 0.001).
In this study, we found that high levels of NGAL at the time of diagnosis were associated with poor prognosis in HCC patients.
Keywordsords: Hepatocellular carcinoma lipocalin-2 Neutrophil gelatinase-associated lipocalin
Compliance with Ethical Standards
This study was conducted in accordance with the ethical standards of the Declaration of Helsinki. The ethical approval was received from the ethical committee of Necmettin Erbakan University Meram Medical Faculty.
Conflict of Interest
The authors declare that they have no conflict of interest.
- 5.Mehmet A, Dertli R. Serum soluble TWEAK concentration is decreased in patients with hepatocellular cancer and low blood levels of sTWEAK are associated with poor survival. Int J Hematol Oncol. 27(2):118–26.Google Scholar
- 12.Lim R, Ahmed N, Borregaard N, Riley C, Wafai R, Thompson EW, et al. Neutrophil gelatinase-associated lipocalin (NGAL) an early-screening biomarker for ovarian cancer: NGAL is associated with epidermal growth factor-induced epithelio-mesenchymal transition. Int J Cancer. 2007;120(11):2426–34.CrossRefGoogle Scholar
- 21.Llovet JM, Brú C, Bruix J, editors. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Seminars in liver disease; 1999: © 1999 by Thieme Medical Publishers, Inc.Google Scholar
- 24.Giasson J, Hua Li G, Chen Y. Neutrophil gelatinase-associated lipocalin (NGAL) as a new biomarker for non-acute kidney injury (AKI) diseases. Inflamm Allergy Drug Targets (Formerly Current Drug Targets-Inflammation & Allergy). 2011;10(4):272–82.Google Scholar
- 35.Duvillard L, Ortega-Deballon P, Bourredjem A, Scherrer M-L, Mantion G, Delhorme J-B, et al. A case–control study of pre-operative levels of serum neutrophil gelatinase-associated lipocalin and other potential inflammatory markers in colorectal cancer. BMC Cancer. 2014;14(1):912.CrossRefGoogle Scholar
- 37.Di Carlo A. The enigmatic role of lipocalin 2 in human cancer. The multifunctional protein neutrophil gelatinase-associated lipocalin (NGAL) and its ambiguous role in human neoplasias. Prevent Res. 2012;2.Google Scholar